Cortice Biosciences Announces Upcoming Presentation At The 19th Annual Scientific Meeting And Education Day Of The Society For Neuro-Oncology
NEW YORK, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that preliminary results from CB-017, a multi-center Phase 1/2 trial evaluating TPI 287 plus bevacizumab (Avastin®) for the treatment of patients with recurrent glioblastoma (GBM) who have not received prior bevacizumab will be presented at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology in Miami Beach, FL. Results will include safety data from the first four cohorts of the dose escalation portion of the study as well as overall response data from patients enrolled to date.
Title: Phase 1/2 trial of bevacizumab plus TPI 287, a novel brain penetrable anti-microtubule agent, for the treatment of recurrent glioblastoma
Date: Friday, November 14
Time: 7:30 – 9:30 PM ET
Poster #: AT-24
Presenter: Samuel Goldlust, M.D., John Theurer Cancer Center, Hackensack, NJ
About TPI 287
TPI 287 is a novel taxoid which binds to and stabilizes the assembly of microtubules similarly to commonly used taxanes, including paclitaxel (Taxol® and Abraxane®) and docetaxel (Taxotere®). In oncology treatment settings, microtubule stabilization by these agents leads to mitotic arrest and cancer cell death. TPI 287 has advantages over the taxanes due to its ability to circumvent common drug resistance mechanisms and its propensity to penetrate the central nervous system. Accordingly, TPI 287 has the potential to treat primary brain tumors and secondary brain metastases that are often shielded from systemic administration of taxanes and other chemotherapeutics. Microtubule stabilization by TPI 287 may also have potential for the treatment of neurologic disorders affected by tau protein pathology. These include tauopathies such as Alzheimer's disease and orphan diseases, such as progressive supranuclear palsy, corticobasal degeneration, and frontotemporal dementia.
About Glioblastoma
Glioblastoma (GBM) is the most aggressive and common form of brain cancer. Five-year survival after diagnosis is about 5%. The Central Brain Tumor Registry estimates that about 22,800 primary malignant brain tumors cases will be diagnosed in the US in 2014, 16% of which will be GBM. Typical front-line treatments include stereotactic or whole brain radiotherapy plus temozolomide (Temodar®). Patients with recurrent disease are candidates for treatment with Avastin®, the last FDA approved agent for this disease.
About Cortice Biosciences
Cortice Biosciences, Inc. is a clinical-stage drug development company pioneering novel therapies for the treatment of oncologic and neurologic disease indications with urgent unmet medical need. More information can be found at www.corticebiosciences.com.
CONTACT: Cortice Biosciences, Inc. 646-747-9090 info@corticebio.com 
Help employers find you! Check out all the jobs and post your resume.